Theravance Biopharma (NASDAQ:TBPH) Given New $17.00 Price Target at B. Riley Financial

Key Points

• B. Riley Financial raised its price target on Theravance Biopharma to $17.00 from $14.00 while maintaining a "neutral" rating, implying about a 3.6% upside from the prior close.
• Analyst sentiment is mixed-to-positive with a consensus rating of "Moderate Buy" and an average price target of $21.83, supported by recent upgrades and higher targets from firms like HC Wainwright ($27).
• Shares traded at $16.41 (market cap ~$845M, PE 8.09) on the report; insiders sold shares (SVP Rhonda Farnum sold 31,067) while institutional ownership remains very high at 99.10%.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) had its price objective raised by research analysts at B. Riley Financial from $14.00 to $17.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. B. Riley Financial's price objective would indicate a potential upside of 3.58% from the stock's previous close.

Several other analysts also recently commented on TBPH. Wall Street Zen cut Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Monday. Weiss Ratings upgraded Theravance Biopharma from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, March 24th. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Thursday, March 19th. HC Wainwright upped their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Finally, TD Cowen increased their price target on Theravance Biopharma from $13.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, March 23rd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.83.

Theravance Biopharma Stock Up 1.9%

TBPH traded up $0.31 on Tuesday, reaching $16.41. The company had a trading volume of 170,583 shares, compared to its average volume of 617,325. Theravance Biopharma has a 1 year low of $8.09 and a 1 year high of $21.03. The stock has a market capitalization of $845.11 million, a PE ratio of 8.09 and a beta of 0.17. The stock has a 50-day moving average price of $16.97 and a 200-day moving average price of $17.00.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently modified their holdings of TBPH. Arrowstreet Capital Limited Partnership acquired a new position in Theravance Biopharma in the third quarter valued at $10,611,000. Assenagon Asset Management S.A. increased its stake in Theravance Biopharma by 1,629.4% during the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company's stock worth $6,055,000 after acquiring an additional 390,735 shares during the last quarter. Pacer Advisors Inc. purchased a new position in shares of Theravance Biopharma in the 4th quarter worth about $6,342,000. Hillsdale Investment Management Inc. acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $4,536,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company's stock valued at $7,493,000 after purchasing an additional 273,288 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.